IMP.VN Imexpharm Corp

Healthcare Drug Manufacturers - Specialty & Generic Vietnam Stocks
Add to portfolio Ask AI about IMP.VN
36,050 VND
Close of Oct 30, 2026
32,650 56,170
Market cap
VND 5.55T
P/E
24.2x
P/B
2.24x
ROE
14.3%
Dividend yield
1.39%
Fundamental score
2.9/5

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is IMP.VN undervalued?

Graham number
Price36,050
Graham value23,242
Premium55.1%

IMP.VN trades 55.1% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Imexpharm Corp fundamental analysis

13 of 22 checks passed

ROE 1/2

Moderate return on equity (14.3%), between 10% and 20%.

ROA 0/1

Return on assets (11.7%) is below the industry median (11.7%).

Profit Consistency 2/2

Profitable for 7 consecutive years.

Earnings Growth 5Y 0/1

Earnings per share did not grow over the past 5 years.

Earnings Acceleration 1/1

Last year's EPS growth (8.8%) is above the 5-year average (-6.3% a year).

Earnings Growth vs Industry 1/1

Last year's EPS growth (8.8%) is above the industry median (5.0%).

Revenue Growth 2/2

Revenue grew 14.1% a year over the past 3 years.

Short-term Liquidity 1/1

Current assets cover short-term liabilities.

Long-term Liabilities 1/1

Current assets cover long-term liabilities.

Debt to Equity 2/2

Low debt to equity (4.1%), 40% or less.

Debt Trend 0/1

Debt to equity history is shorter than 5 years.

Debt Coverage 1/1

Operating cash flow covers 20% of total debt.

Interest Coverage 1/1

EBIT is 37.5x against interest expense, well covered.

PE vs Market 0/1

PE (24.2x) is above the market median (11.2x).

PE vs Industry 0/1

PE (24.2x) is above the industry median (13.1x).

PBV 0/1

Price to book (2.2x) is above the industry median (2.2x).

Graham Number 0/1

The price is above the Graham number (PE x PB = 54.1, limit 22.5).

PEG 0/1

PEG needs positive PE and positive 5-year earnings growth.

Dividend Yield 1/2

Dividend yield (1.4%) is above the bottom 25% of dividend payers in the market.

Dividend Stability 0/2

Dividends were not paid steadily for the past 5 years.

Dividend Growth 1/1

Dividends paid grew over the past 5 years.

Payout Ratio 1/1

Payout ratio is 22.1%, covered by earnings.

Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score

Imexpharm Corp stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Imexpharm Corp

Imexpharm Corporation operates as a pharmaceutical company in Vietnam. The company's products include injectable antibiotics, oral antibiotics, cardiovascular, ophthalmology, musculoskeletal system, analgesic - anti-inflammatory - antipyretics, respiratory system, antihistamines and anti-allergy, central nervous system, digestive system, diabetes, anti-parasitic, external drugs, vitamins and minerals, and supplements. It is also involved in the import and export. Imexpharm C…

Full company profile